The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical. The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use […]
Fresenius closes $2B NxStage buyout, settles FCPA case for $255m
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said today that it closed the $2 billion acquisition of NxStage Medical and settled self-reported violations of the U.S. Foreign Corrupt Practices Act for nearly $255 million. The $30-per-share deal for the Lawrence, Mass.-based home hemodialysis pioneer, first announced in August 2017, was initially slated to close by the end of that year. […]
FTC gives the go ahead to Fresenius, NxStage merger
The U.S. Federal Trade Commission said yesterday that it cleared Fresenius (NYSE:FMS) in its $2 billion acquisition of NxStage Medical (NSDQ:NXTM). As part of the approval, NxStage will have to part ways with its bloodline tubing set business, offloading them to B. Braun, according to the regulatory agency. The vote to approve the merger was split, however, […]
U.S. gov’t shutdown again delays closing for Fresenius-NxStage merger
Fresenius (NYSE:FMS) said today that an interruption to the FTC’s review of its merger with NxStage Medical (NSDQ:NXTM), caused by the partial U.S. government shutdown, has again delayed the end-date of the deal which has now been extended to August 6, 2019. The end-date is not hard-set, Fresenius said, and could occur on an earlier date if there have […]
Fresenius still awaiting FTC approval for NxStage acquisition
Fresenius (NYSE:FMS) said last Friday that it is still in the process of seeking approval from the U.S. Federal Trade Commission for its $2 billion merger with NxStage Medical (NSDQ:NXTM). The tie-up, which was delayed by NxStage in October in light of the FTC investigation, has been in the works for nearly a year and a half, having […]
NxStage Medical, Fresenius again delay $2B merger
NxStage Medical (NSDQ:NXTM) yesterday once more delayed its pending $2 billion merger with Fresenius (NYSE:FMS) as the U.S. Federal Trade Commission continues to examine the deal. In July, the German renal care giant and Lawrence, Mass.-based NxStage extended the deal’s closing date by 90 days, from August 7 to Nov. 5, saying it still expected to close the deal this year. […]
NxStage touts home hemodialysis study data
NxStage Medical (NSDQ:NXTM) today released data from a study comparing home hemodialysis to traditional treatment in a skilled nursing facility, touting a lower risk of death and cardiovascular hospitalization for those treated more often with home hemodialysis. Full results from the trial are slated to be presented at the American Society of Nephrology Kidney Week 2018 […]
Fresenius extends deadline for $2B NxStage buyout, tops Q2 earnings forecast
Fresenius (NYSE:FMS) said today that it’s extending the deadline to close the $2 billion buyout of NxStage Medical (NSDQ:NXTM) by 90 days and posted second-quarter earnings that beat the consensus forecast. The German dialysis giant said it moved the merger deadline from August 7 to Nov. 5, but still expects to close the deal this year. […]
UPDATE: NxStage deals bloodlines biz to B Braun to mollify FTC in sale to Fresenius
UPDATE: Now includes information from NxStage indicating that the sale was part of the process to obtain FTC clearance for its sale to Fresenius. B. Braun said today it inked a deal to acquire the NxStage Medical‘s (NSDQ:NXTM) bloodlines business, which operates under the Medisystems moniker. Bethlehem, Penn.-based B. Braun did not release any details of the […]
NxStage touts reduced technique failure in Nx2me home hemodialysis study
NxStage Medical (NSDQ:NXTM) today released the results from a study of its Nx2me connected health remote patient management system for patients using home hemodialysis, touting a 29% reduction in technique failure of conversion to in-center hemodialysis by 29%. Results from the study were published in the journal Hemodialysis International, the Lawrence, Mass.-based company said. Data came from […]
NxStage shares dip on Q3 EPS miss
Shares in NxStage Medical (NSDQ:NXTM) have fallen slightly today after the medical device maker missed expectations on Wall Street with its third quarter earnings results. The Lawrence, Mass.-based company posted losses of $8.9 million, or 14¢ per share, on sales of $97.3 million for the 3 months ended September 30, seeing losses grow nearly 900% while […]
- 1
- 2
- 3
- …
- 12
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube